RxDoctor Payments Data

Mark Liwanag, DO

Clinical Cardiac Electrophysiology · Flagstaff, AZNPI 1932514858

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (37.2%), travel and lodging and grants — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Medtronic at 51.8% of the total. Reporting peaked in 2021 at $9,828 and has fallen 90.6% since, to $920 in 2025. That places this record below the midpoint for clinical cardiac electrophysiology clinicians in AZ, where the typical reported total is $29,180.

$19,210in general payments, 2019–2025

Across 173 payments — averaging $111.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$10K
  • Abbott$4K
  • Boston Scientific$3K
  • Cardiva Medical, Inc.$432
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$276
  • Bracco Diagnostics Inc.$247
  • plus $1K from 17 others

What the payments were for

  • Grants$5,00026%
  • Travel & lodging$6,62234%
  • Food & beverage$7,15237%
  • Education$4362%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,210 in reported general payments places this provider in the 40th percentile of 80 clinical cardiac electrophysiology providers in Arizona.

See all clinical cardiac electrophysiology providers in Arizona

Medicare billing

Part B allowed, 2024
$333,439
Medicare patients
1,268
Services billed
4,306

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban186$160,257
XareltoRivaroxaban56$46,052
Dofetilide14$2,883
Flecainide Acetate69$2,500
Metoprolol Succinate246$2,499
Amiodarone Hcl58$685
Pantoprazole Sodium44$401
Sucralfate23$290
Losartan Potassium26$186
Amlodipine Besylate23$78
Atorvastatin Calcium12$56
Furosemide13$47

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$67$160,257186 claims
Johnson & JohnsonXarelto$49$46,05256 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 80 clinical cardiac electrophysiology providers in Arizona.

Other clinical cardiac electrophysiology in Flagstaff

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →